With shares of International Business Machines�(NYSE:IBM) trading around $194 after IBM’s earnings, is the stock an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
International Business Machines (NYSE:IBM) is an information technology company that operates in five segments: Global Technology Services, Global Business Services, Software, Systems and Technology, and Global Financing. Global Technology Services�provides information technology infrastructure services and business process services. Global Business Services�provides professional services and application management services. Software consists of middleware and operating systems software. Systems and Technology provides clients with business solutions requiring advanced computing power and storage capabilities. Global Financing invests in financing assets, leverages with debt and manages the associated risks. Through its segments, IBM is able to provide information technology products and services to a wide variety of companies participating in diversified sectors, worldwide.
Top 5 Airline Stocks To Buy For 2015: Black Box Corporation(BBOX)
Black Box Corporation provides network infrastructure services for communications systems worldwide. Its services include design, installation, integration, monitoring, and maintenance of voice, data, and integrated communications systems. The company also offers voice communications solutions, technology product solutions, premises cabling, and other data-related services, as well as provides technical support services for its solutions, which include hotline services, consultation, site surveys, design and engineering, project management, single-site and multi-site installations, remote monitoring, and certification and maintenance of voice, data, and integrated communication solutions. It sells its products and services to small organizations, corporations, and institutions through its catalogs, on-site services offices, and Internet Web site. The company was founded in 1973 and is headquartered in Lawrence, Pennsylvania.
Advisors' Opinion:- [By Rich Duprey]
Communications specialist�Black Box (NASDAQ: BBOX ) announced today its third-quarter dividend of $0.09 per share, the same rate it paid last month after raising the quarterly payout 12.5% from $0.08 per share.
- [By Evan Niu, CFA]
What: Shares of Black Box (NASDAQ: BBOX ) have popped today by more than 19% after the company reported earnings and boosted its dividend.
- [By Jake L'Ecuyer]
Top losers in the sector included China Unicom (Hong Kong) (NYSE: CHU), off 4.5 percent, and Black Box (NASDAQ: BBOX), down 3 percent.
Top Headline
The Boeing Company (NYSE: BA) reported better-than-expected first-quarter profit. Boeing's quarterly profit declined to $965 million, or $1.28 per share, from a year-ago profit of $1.11 billion, or $1.44 per share. Its adjusted earnings surged to $1.76 per share compared to $1.73 per share. Its revenue climbed to $20.47 billion versus $18.89 billion. However, analysts were projecting earnings of $1.57 per share on revenue of $20.24 billion. For the full year, Boeing expects adjusted earnings of $7.15 to $7.35 per share.
Hot Information Technology Companies To Watch For 2014: Noah Holdings Ltd (NOAH)
Noah Holdings Limited, incorporated on June 29, 2007, through its subsidiaries is a service provider focusing on distributing wealth management products to the high net worth population in the People�� Republic of China (PRC). The Company provides direct access to China�� high net worth population. Noah Holdings Limited is a holding company and it operates its business through its PRC subsidiary, Shanghai Noah Rongyao Investment Consulting Co., Ltd (Noah Rongyao), its variable interest entity, Shanghai Noah Investment Management Co., Ltd (Noah Investment), and their respective subsidiaries in China. While Noah Rongyao conducts most of the Company�� businesses, it conducts its insurance brokerage business through Noah Investment and its subsidiaries. Its products choices consist of over-the-counter (OTC) products originated in China and designed to cater to the needs of high net worth population.
With over 300 relationship managers in 28 branch offices, the Company�� coverage network encompasses China�� economically developed regions where high net worth population is concentrated, including the Yangtze River Delta, the Pearl River Delta and the Bohai Rim. Through this coverage network, it serves high net worth individuals, enterprises affiliated with high net worth individuals and wholesale clients, primarily local commercial banks or branches of national commercial banks, which distribute wealth management products to their own clients. Its registered clients were 12,353 as of June 30, 2010. The number of its active clients was 779 as of June 30, 2010. Noah Holdings Limited distributes OTC, wealth management products originated in China. Its product choices primarily include fixed income products, private equity funds and securities investment funds.
Noah Holdings Limited markets and distributes various categories of products supplied by third party product providers, which include fixed income products, mainly including collateralized fixed income products sponso! red by trust companies and other products that provide investors with fixed rates of return; private equity funds products, including investments in private equity funds sponsored by domestic and internal fund management firms; securities investment funds, which are privately raised funds investing in publicly traded stocks, and investment-linked insurance products. It generates revenues primarily from one-time commissions and recurring service fees paid by third-party product providers or, for the majority of fixed income products, by the underlying corporate borrowers. Its one-time commissions accounted for 78.6% of its net revenues during the year ended December 31, 2009, and its recurring service fees accounted for 21.4% of its net revenues in 2009.
The Company competes with China Merchants Bank, China Minsheng Bank and China Everbright Bank.
Advisors' Opinion:- [By Belinda Cao]
Noah Holdings Ltd. (NOAH), a Chinese wealth-management company, jumped to the highest level in more than two years in New York after raising its 2013 profit estimate.
Hot Information Technology Companies To Watch For 2014: Neuralstem Inc (CUR)
Neuralstem, Inc., incorporated in 1997, is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells.
In October of 2011, the Company announced that after reviewing safety data from the first 12 patients, the FDA granted approval for the trial to advance to transplanting patients in the cervical (upper back) region for the last six patients in the trial. As of December 31, 2011, the Company had treated 14 patients. In February of 2011, the Company commenced a Phase Ia clinical trial of its drug compound, NSI-189, which is being developed for the treatment of depressive disorder and other psychiatric indications. In October of 2011, the Company completed the Phase Ia portion of the trial. In December of 2011, the Company received approval from the FDA to commence the Phase Ib portion of the trial.
During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011. The Company has developed and patented a series of small molecule compounds (low molecular weights organic compounds which can efficiently cross the blood/brain barrier).
Advisors' Opinion:- [By Roberto Pedone]
An under-$10 biotechnology player that's starting to enter breakout territory is Neuralstem (CUR), which is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. This stock has been exploding to the upside in 2013, with shares up big by 139%.
If you take a look at the chart for Neuralstem, you'll notice that this stock has been uptrending strong for the last month and change, with shares pushing higher from its low of $2.15 to its intraday high of $2.62 a share. During that uptrend, shares of CUR have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now started to push shares of CUR above a key downtrend line, which is bullish technical price action.
Traders should now look for long-biased trades in CUR if it manages to break out above some near-term overhead resistance levels at $2.75 to $2.97 a share, and then once it takes out its 52-week high at $3.02 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1.10 million shares. If we get that move soon, then CUR will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $4 to $5 a share.
Traders can look to buy CUR off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $2.28 to $2.15 a share. One can also buy CUR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Roberto Pedone]
Neuralstem (CUR) is a biotechnology company, which is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. This stock closed up 6.1% to $1.72 in Thursday's trading session.
Thursday's Range: $1.59-$1.72
52-Week Range: $0.49-$1.96
Thursday's Volume: 590,000
Three-Month Average Volume: 474,694From a technical perspective, CUR ripped higher here right above its 50-day moving average of $1.57 with above-average volume. This move is quickly pushing shares of CUR within range of triggering a major breakout trade above a former double top area. That trade will hit if CUR manages to take out some near-term overhead resistance levels at $1.75 to $1.79 with high volume.
Traders should now look for long-biased trades in CUR as long as it's trending above its 50-day at $1.57 or above more key support levels at $1.55 to $1.43 and then once it sustains a move or close above those breakout levels with volume that hits near or above 474,694 shares. If that breakout hits soon, then CUR will set up to re-test or possibly take out its 52-week high at $1.96. Any high-volume move above that level will then give CUR a chance to tag $2.20 to $2.50.
- [By John Udovich]
The results of a recent Pew Center Poll regarding attitudes towards abortion and various forms of stem cell research could be a good sign for the stem cell industry along with small cap stem cell stocks like StemCells Inc (NASDAQ: STEM), NeoStem Inc (NASDAQ: NBS), Neuralstem, Inc (NYSEMKT: CUR),�International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX). Basically, Americans think that having an abortion is a moral issue with 49% of American adults believing abortion is morally wrong, 23%�view it not as a moral issue and and 15% view it as morally acceptable. However and when Americans were asked about issues surrounding�human embryos, such as stem cell research or in vitro fertilization, as a matter of morality, their views were different.
Hot Information Technology Companies To Watch For 2014: Therapeutic Solutions International Inc (TSOI)
Therapeutic Solutions International, Inc., formerly Friendly Auto Dealers, Inc., incorporated on August 6, 2007, is a development-stage company. The Company is focused in establishing itself as a specialized brand promotional merchandising company. It would identify a range of casual apparel and consumer products that can be manufactured and resold with the product endorsement of corporate logos. In April 2011, the Company acquired Splint Decisions Inc.
The Company concentrates its efforts in the People�� Republic of China and its retail automotive industry. As of December 31, 2009, the Company had no operations and had not generated any revenues.
Advisors' Opinion:- [By Peter Graham]
Small cap medical device or biotech related stocks Therapeutic Solutions International Inc (OTCMKTS: TSOI), diaDexus, Inc (OTCMKTS: DDXS) and Spherix Inc (NASDAQ: SPEX) have been getting some attention lately in various investment newsletters with the good news being that it appears none are the subject of paid promotions from stock promoters. So why are these three stocks all of a sudden getting some attention and what else do you need to know about them before you make a short or a long term bet on one? Here is a closer look at the whole picture and what you might be missing:
Hot Information Technology Companies To Watch For 2014: Tonix Pharmaceuticals Holding Corp (TNXP)
Tonix Pharmaceuticals Holding Corp., incorporated on November 16, 2011, is a specialty pharmaceutical company focused on developing novel pharmaceutical products for disorders of the central nervous system (CNS). The Company develops TNX-102 sublingual tablet, or TNX-102 SL. TNX-102 SL is a novel dose and formulation of cyclobenzaprine (CBP), the active pharmaceutical ingredient of two prescribed muscle relaxant products, Flexeril and Amrix. TNX-102 SL is also intended for chronic use. It develops TNX-102 SL for the treatment of FM under a United States Investigational New Drug application (IND), and under three clinical trial applications (CTAs), filed in Canada. It also develops TNX-102 SL for the treatment of post-traumatic stress disorder (PTSD). As of January 25, 2013, the Company focuses on product development, and had not generated any revenues.
The Company searches for potential therapeutic solutions among known pharmaceutical agents that lack regulatory approval for the indications it seeks, but may be approved for use in other indications. It seeks to create new dose and formulation options that are tailored to the therapeutic uses to which it applies these agents. TNX-102 SL is a small, rapidly disintegrating tablet containing CBP for sublingual administration at bedtime. The Company designed TNX-102 SL for delivery of CBP to the systemic circulation through sublingual transmucosal absorption and to avoid first-pass liver metabolism.
CBP is the active pharmaceutical ingredient in its lead product candidate, TNX-102 SL. In addition to CBP, TNX-102 SL contains inactive ingredients, called excipients, which are approved for pharmaceutical use. In addition to TNX-102 SL, it develops other formulations of CBP, including TNX-102 promicellar gelatin capsule, or TNX-102 gelcap. It developed TNX-102 gelcap under an agreement with Lipocine, Inc. (Lipocine), a contract formulation developer and small-scale manufacturer. In addition it has other pipeline of other product cand! idates, including TNX-201 and TNX-301. TNX-201 is based on isometheptene mucate and is under development as a treatment for certain types of headaches.
Advisors' Opinion:- [By John Kell]
Tonix Pharmaceuticals Holding Corp.(TNXP) is planning to offer some shares to raise money to fund clinical trials and the continued development of the specialty pharmaceutical company’s treatments. Shares edged up 2.1% to $16.75 premarket.
- [By John Udovich]
It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:
No comments:
Post a Comment